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Background: The healthy properties of conjugated linoleic acid (CLA) such as weight loss, reducing cardiovascular
risk factors and inflammation have been reported. The trans-10, cis-12 CLA isomer is related to increasing insulin
resistance, but the effects of cis-9, trans-11 isomer is not clear. The aim of this study was to investigate the effects
of CLA with and without Vitamin E on body weight, body composition, glycemic index, inflammatory and
coagulation factors, lipid profile, serum leptin and adiponectin, malondialdehyde (MDA), and blood pressure in
type2 diabetes.
Methods: 56 patients with type2 diabetes were included in 8 week double-blind control trial that used metformin.
They randomly divided into three groups: CLA + VitE, CLA + VitE placebo, CLA placebo + VitE placebo. All variables,
anthropometric measurements, and body composition were evaluated at the beginning and the end of study.
Statistical analysis and analysis of dietary data were performed using SPSS and nutritionist IV software, respectively.
Results: There were not any significant differences in variable changes among three groups. However, there was a
trend to increase in MDA and decrease in apoB100 among CLA consumers.
Conclusion: The results of this study showed that administration of CLA supplementation for 8 weeks does not
affect any indicators of metabolic control in overweight type2 diabetic patients.
Keywords: CLA, VitE, Inflammatory factors, Type2 diabetesBackground
Conjugated linoleic acid (CLA) is referred to a group of
18 carbon unsaturated fatty acids with two double bond
that is isomers of octadecanoic acid [1,2]. Normally,
CLA is produced in the rumen of ruminants through
partial biohydration or bacterial fermentation as the first
intermediate of linoleic to stearic acid transformation or
from trans-11 octadecanoic acid (vaccenic acid) by delta
9-desaturase (oxidation) [3]. Therefore, the major food
sources of this unusual fatty acid are ruminant pro-
ducts (meat and milk). Some studies have reported* Correspondence: Hedayati@endocrine.ac.ir
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reproduction in any medium, provided the oruseful properties for CLA such as anti-obesity [4-6],
anti-Atherogenic [7,8], anti-diabetic [9-11] and anti-
inflammatory properties [12].
Two active isomers of CLA that have been investigated
so far are cis-9, trans-11 and trans-10, cis-12 that first
one is more dominant in dairy products [3,13]. These
isomers have several effects in different biological sys-
tems and their effects are similar or different sometimes
[2]. Results of some studies have shown that trans-10,
cis-12 isomers are the active form of CLA reduces body
weight and fat accumulation [5]. However, in some cases
this isomer lead to worsening peripheral insulin sensitiv-
ity and increased concentrations of blood glucose, free
fatty acids, and lipid profiles [14-17] and cis-9, trans-11
isomer reduces serum triglyceride levels and plasma free
fatty acids [2]. However, the results of 50:50 isomerral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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index and inflammation are controversial [10,18].
Animal studies have shown that isomer trans-10, cis-
12 isomers of CLA increase insulin resistance, but the
results of studies on cis-9, trans-11 isomer and mixtures
(50:50) is contradictory. In some animal studies, CLA
had no effect on the blood glucose and insulin resistance
[12,19]. Also, various researches have shown that CLA,
even in different species of animals have different effects.
For example, in rats, CLA increases PPAR-γ expression
as a ligand for this receptor and in this way plays its role
in controlling insulin resistance. Also, CLA decreases in-
sulin resistance in adipose tissue of rats. But some stud-
ies have shown that CLA increases insulin resistance on
mice [19].
Also, the results of CLA supplementation on type II
diabetic patients are inconsistent. One of the possible
reasons may be the types of consuming drugs, hetero-
geneity of population in the cases of age, BMI and etc.
[7,20].
In some studies supplementation of CLA led to incre-
ment in oxidative stress and inflammation [9,21]. Since
these conditions are related to diabetes, we suppose that
supplementation with vitamin E may compensate the
possible effects of CLA on oxidative stress and diabetes
control. Furthermore, regarding the decrement of Anti-
oxidant capacity in diabetic patients, it raises the possi-
bility that this issue in previous studies may mask some
effects of CLA or lead to a slight increase in insulin re-
sistance. Regarding the possible intake of CLA supple-
ments among type 2 diabetic patients to lose weight and
tendency of some food industries such as dairy products
and oil to enrich their products with CLA,
So, the aim of current study is to investigate the effects
of CLA alone and combined with VitE on glycemic re-
sponse, cardiovascular risk factors, inflammatory indica-
tors, malondialdehyde (MDA) and some adipocytikines
associated to diabetes and obesity. Important notable ex-
cellence of our study is that to date no well designed
controlled study with such inclusion criteria on type 2
diabetic patients has been done.
Methods
This study was approved by the Ethic Committee of In-
stitute of Food Technology and Nutrition research, Sha-
hid Beheshti University of Medical Sciences and was
conducted in 2008 at Research Institute for Endocrine
Sciences (RIES), Tehran, Iran.
Sixty-three participants with type2 diabetes whose dia-
betes was controlled by metformin were recruited and
56 completed the trial. At the beginning, the protocol
and the aim of study were fully explained to the partici-
pants and written informed consent was obtained from
each volunteers. Inclusion criteria, including diagnosedtype2 diabetes mellitus for more than 5Y, diagnosis after
30 years old, age of 35 to 50Y, body mass index
(BMI; in kg/m2) >25 and <30 and fasting blood glu-
cose of 126–180 mg/dl. Exclusion criteria were the
history of myocardial infarction, angina pectina and
stroke, diagnosis of cardiovascular disease, liver or renal
disease or chronic inflammatory and thyroid disease, be-
ing vegetarians or vegans, smoking, consuming of alcohol
and any supplements (e.g. vitamins such as C and E, fish
oils, CLA, etc.) 2 months before intervention, pregnancy
and menopause.
The study was an eight weeks randomized double
blind, placebo-controlled (RCT) parallel intervention.
The participants were stratified according to their sex,
age and BMI into one of three groups (A, B, and C) re-
ceiving 3.0 g CLA/d (3×1 g capsules; a 50:50 isomer
blend of c-9, t-11 and t-10, c-12 CLA) with 100 IU/d
VitE, 3.0 g CLA/d with VitE placebo, or CLA placebo
(soy bean oil) and VitE placebo respectively. Ineffective-
ness of soybean oil as a placebo in the quantities being
used in this study on reviewed variables has shown in
other studies [20]. The CLA used in this study was
Tonalin SG1000T FFA and soft gelatin capsules with clear,
transparent shell and pale amber fill. They contain
Tonalin FFA 80 i.e., free fatty acids containing about 80%
conjugated Linoleic. All supplements were supplied by
Cognis, Norway. Each volunteers received the capsules in
2 batches, at the beginning of the study. All participants
were asked to maintain their usual physical activity and
dietary and lifestyle habits and these were checked by food
record and physical activity questionnaire. There was no
change in prescribed medication throughout the trial.
Acceptance of the supplements was investigated via
weekly phone calling and meetings through asking and
counting the remaining capsules in the package delive-
red. During these calls possible problems such as supple-
ment intolerance and medication use, possibly changes
in food consumption, getting a new disease or a change
in physical activity was followed and if this situation
occurred, the patient desired were excluded. In the
fourth and eighth weeks of study through counting
the remaining capsules, compliance rates of patients
was evaluated and patients were not consumed more
than ten percent of received capsules, were excluded
from the study.
To evaluate the mean dietary intake two 1-d 24-h food
recall and 2-d food records (one day a week holiday)
were used on the baseline and the end of the fourth and
eighth week of the study. In the first taking the 24 days
recall, how to diet properly recording, including how to
weigh and measure food was trained by an expert. This
dietary information was analyzed with N4 software
(Nutritionist: version 4.0; Tinuviel Software, Warrington,
United Kingdom).
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no shoes on a digital balance (with 0.1 kg sensitivity).
Height was assessed by using a stadiometer that mea-
sured to the nearest 0.1 cm. Body mass index (BMI) was
estimated as the ratio of body weight to height squared
and expressed as kg/m2. Waist circumference (with
0.1 cm sensitivity) was measured at the minimum cir-
cumference between the iliac crest and the last rib cage
at the end of exhalation. The hip circumference was
measured using tape as the maximal circumference over
the hip and Waist-to-hip ratio (WHR) was calculated
[22]. Bioelectrical impedance analysis was used to meas-
urement of body fat and lean percentage (Body Stat
1500, Douglas Isle of man, British islets, England). For
this purpose, first two glasses of water consumed by pa-
tients and after one hour and urination without any
metal on the body, body composition was measured.
Measuring body composition was done in lying state
and installing the electrodes to the right hand and foot.
Patients were taught avoiding intense activity the day be-
fore testing [23]. These measurements were done at the
beginning and end of the study.
Blood pressure measuring was done to the nearest
2 mmHg, after resting for at least 15min and sitting on
the seat handle. Right arm blood pressure was measured,
twice, at least five minutes interval, by Korotkoff ’s aus-
cultatory method at the beginning and end of the study.
Seven ml 12-hour fasting state and 3 ml postprandial
brachial vein blood samples were taken at the baseline
and end of eighth week and blood collected into EDAT
containing tubes. A standard breakfast in diabetic pa-
tients is contained about 360kcal, including: 56.6 g car-
bohydrate (50-55% Cal), 19.5g protein (15-20% Cal) and
11.5 g fat (30% Cal) [24,25]. Localized standard breakfast
for Iranians that has been used in previous studies in-
cluded two servings bread; one serving cheese, 2x dates,
and four small cubes that total provided about 390kcal
and 14g protein [26]. To maintain comparability of Iran-
ian studies with the international studies in which the
breakfast induced energy is 360 kcal, and also given that
patients participating in this study did not normally use
refined s such as in the diet, of breakfast was removed
and replaced as a number of dates were added to the
breakfast.
Serum glucose concentration was measured by using
enzymatic colorimetric method according glucose oxi-
dase principle (Glucose determination kit, Parsazmun,
Tehran, Iran) through auto-analyzer instrument (Sellectra
II, Dieren, Netherland). Serum insulin, proinsulin and C-
peptide levels were measured by Enzyme Linked Immuno
assay (ELISA) kit (Mercodia AB, Uppsala, Sweden). Gly-
cated hemoglobin was determined on whole blood sample
by ion exchange chromatography method (HbA1c Kit,
Inter Medical, Villaricca, Italy).The intra assay coefficient of variation (CV%) for glu-
cose, insulin, proinsulin, C- peptide and HbA1c were
4.7%, 5.5%, 4.5%, 4.7% and 5.6% and the inter assay coef-
ficient of variation were 4.9%, 5.8%, 4.9%, 5%, and 5.8%
respectively. The assays sensitivity was 1mg/dl, 1mU/L,
0.5 pmol/l, 5 pmol/l and 1% respectively.
Insulin resistance was calculated according the homeo-
stasis model of assessment ratio (HOMA-IR) formula, as
an index of insulin resistance:
[Insulin (μU/ml)×glucose (mmol/L)]/22.5 [27]. That
5<HOMA IR is defined as insulin resistance and 3>
HOMA IR as not-insulin resistance [28].
Insulin sensitivity was calculated from following for-
mula [29]:
QUICKI ¼ 1= log glucose0 þ log insulin0
  
:
And beta cell function determined through proinsulin/
insulin ratio [30]. Beta cell function index as HOMA-B%
and C-peptide to insulin molar ratio as an index of liver
insulin clearance was calculated [31].
Fasting b-cell responsiveness (M0) represents the abil-
ity of fasting glucose to stimulate b-cell secretion and
postprandial b-cell responsiveness (M1) represents the
ability of postprandial glucose to step up b-cell secretion
and they were calculated using the formula of Hovorka
et al. [32].
M0 ¼ 100 fasting C–peptide μg=lð Þ=fasting glucose mg=dlð Þ
M1 ¼ 100 ðpostprandial 2 h C−peptide−fasting C−peptide=
postprandial 2 h glucose–fasting glucoseð Þ
Serum concentration of triglyceride and HDL choles-
terol were measured using kits and enzymatic colorimet-
ric method (Parsazmun, Tehran, Iran). Total cholesterol
Concentration was measured by enzymatic photometric
method kits (Parsazmun, Tehran, Iran). LDL cholesterol
concentration calculated using the Friedewald formula.
Also, the ratio of LDL to HDL cholesterol concentra-
tions was calculated. The intra assay coefficient of vari-
ation (CV%) for triglycerides, total cholesterol and HDL
cholesterol were 2.7%, 2.3% and 5.1% and the inter assay
coefficient of variation were 2.9%, 2.5T and 5.5% respec-
tively. Also, the related assays sensitivity was 1 mg/dL,
3mg/dL and 1mg/dl respectively.
Serum leptin levels were measured by Enzyme Linked
Immuno assay (ELISA) kit (Diagnostics Biochem Canada
Inc., ontario, Canada). Serum adiponectin levels were
measured by Enzyme Linked Immuno assay (ELISA) kit
(Mercodia AB, Uppsala, Sweden). The intra assay coeffi-
cient of variation (CV%) for leptin and adiponectin were
2% and 1.5% respectively and the inter assay coefficient







Age (year) 47.6 ± 3.8 45.1 ± 5.7 45.5 ± 4.3
Sex (N)
Male 8 9 9
Female 9 10 11
Weight (Kg) 77.2 ± 13.1 77.6 ± 10.9 73.1 ± 9.4
BMI (Kg/m2) 28.1 ± 2.4 27.4 ± 0.5 27.1 ± 1.8
Waist circumference (cm)
Male 96.4 ± 9.2 93.0 ± 7.2 91.1 ± 5.7
Female 86.3 ± 9.2 88.8 ± 7.7 89.0 ± 5.8
Fat %
Male 28.1 ± 3.8 22.2 ± 7.8 26.1 ± 7.2
Female 41.5 ± 6.0 40.5 ± 7.8 34.1 ± 8.0
FBG (mg/dl) 155.5 ± 15.4 154.1 ± 14.1 155.5 ± 20.2
HbA1c% 9.4 ± 1.6 10.4 ± 1.5 10.4 ± 1.7
BMI Body Mass Index, FBG Fasting Blood Glucose.
A group: 3.0 g CLA/d (3×1 g capsules; a 50:50 isomer blend of c-9, t-11 and
t-10, c-12 CLA) with 100IU/d VitE.
B group: 3.0 g CLA/d with VitE placebo.
C group: CLA placebo (soy bean oil) and VitE placebo.
Table 2 Dietary intake in patients with type 2 diabetes
(experimental group=17, = 21 positive controls and











A (N=17) 2.0 ± 0.3 2.2 ± 0.28 2.7 ± 0.27 0.95
B (N=21) 1.9 ± 0.25 2.2 ± 0.23 2.0 ± 0.15 0.95
C (N=20) 1.8 ± 0.12 1.7 ± 0.25 1.9 ± 0.23 0.93
Meat (serving)
A (N=17) 2.1 ± 0.23 2.0 ± 0.35 2.2 ± 0.23 0.8
B (N=21) 1.9 ± 0.30 1.9 ± 0.25 1.8 ± 0.27 0.9
C (N=20) 2.0 ± 0.21 1.8 ± 0.23 1.8 ± 0.11 0.8
Cereals (serving)
A (N=17) 11.12 ± 2.03 12.75 ± 1.76 11.5 ± 2.55 0.85
B (N=21) 12.15 ± 1.05 12.75 ± 0.3 12.12 ± 1.12 0.8
C (N=20) 11.43 ± 1.11 12.34 ± 0.81 12.23 ± 0.91 0.89
Fruit (serving)
A (N=17) 2.2 ± 0.09 2.65 ± 0.49 2.0 ± 0.54 0.82
B (N=21) 1.9 ± 1.01 2.09 ± 0.45 2.0 ± 0.87 0.8
C (N=20) 1.8 ± 1.12 1.8 ± 1.54 2.01 ± 1.12 0.9
Vegetables
(serving)
A (N=17) 1.6 ± 0.27 1.9 ± 0.14 1.7 ± 0.34 0.79
B (N=21) 1.3 ± 0.09 2.1 ± 0.65 1.4 ± 0.21 0.88
C (N=20) 1.4 ± 0.11 1.6 ± 0.23 1.6 ± 0.65 0.65
Energy (Kcal)
A (N=17) 1996 ± 198 1919 ± 255 1983 ± 211 0.82
B (N=21) 1978 ± 234 1950 ± 199 1975 ± 240 0.7
C (N=20) 1999 ± 222 1980 ± 198 2003 ± 201 0.76
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says was 0.50 ng/ml and 1.25 ng/ml respectively.
Serum concentrations of interleukin-1 beta, interleukin-
6 and TNF-α were measured using ELISA kits (Diaclone,
France) and CRP concentration using ELISA kit (Diagnos-
tics Biochem Canada Inc., Ontario, Canada). Intra assay
coefficient of variation of inflammatory IL-1 beta, interleu-
kin 6, CRP and TNF-α, were 7.1%, 4.6%, 1.8%, 3% and the
related inter assay coefficient of variation were 7%, 4.7%,
2% and 3.2% respectively. Sensitivity of assays were also
7 pg/ml, 2 pg/ml, 10 ng/ml and 8 pg/ml. Measuring fib-
rinogen concentration and PAI-1was done using ELISA
kits (Hyphen BioMed, Neuville-Sur-Oise, France) and
MDA concentration by using the colorimetric method
kit (Cayman Chemical Company, Ann Arbor, USA).
The intra and inter assay coefficient of variation for
fibrinogen and PAI-1, were 2.6%, 3.2% and 3%, 3.5%
respectively and assays sensitivity were 1 mg/ml and
0.5 ng/ml respectively. These values for apoB-100 and
MDA were 1.4%, 3% and 2%, 3.5% and 0.1 μg/dl,
1 μmol/L respectively.
Statistical analysis
All statistical tests were performed with the use of SPSS
(version 13.0; SPSS Inc, Chicago) and a p-value<0.05
showed statistical significance. Normality and homogen-
eity of variance was tested with Kolmogrov-Smirinov.
ANOVA test were used to compare mean differences be-
fore and after intervention for anthropometric data and
body composition. Other changes were compared usingANCOVA test adjusted to body composition and waist
circumference. To compare food consumption at the
baseline and end of the fourth and eighth weeks among
groups, and comparison of food consumption in each
group among baseline and end of the fourth and eighth
weeks of study the ANOVA test and repeated measure
ANOVA test were used.
Results
Among 63 individuals participated in this research, one
patient was excluded due to reporting heartburn and di-
gestive discomfort, one due to herbal drug use and five
patients due to not taking the supplements regularly. At
the end, 56 (30females and 26males) completed the
study. Baseline characteristics of patients of A, B, and C
groups listed in Table 1.
Patients’food intakes at the baseline, the end of the
fourth and eighth weeks has been shown in Table 2.
During the study, participants’ food intake did not
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tary SFA, MUFA and PUFA and also, physical activity
level and no changes were shown. Data was not shown
in article.
Table 3, 4, and 5 summarize the results of supplemen-
tation on the studied variables.
Discussion
In this study, consumption of CLA alone and in combin-
ation with VitE did not result in significant changes in
any of the measured variables.
So far, few studies regarding the effect of CLA has
been done in diabetic patients. In a study, usual dose of
commercial CLA supplement improved the insulin sen-
sitivity index in young diabetic adults, but some dif-
ferences were observed in their responsiveness [10]. In
another study, supplemental CLA significantly increased
fasting glucose concentrations and reduced insulin sensi-
tivity (homeostasis model), oral glucose insulin sensiti-
vity and insulin sensitivity index (ISI) [7], while in our
study any of related parameters were not affected. In-
consistency in the results of studies on diabetic patients
may be due to differences in patients ‘responsiveness. As
shown in Eyjolfson et al. study, despite average incre-
ment in insulin sensitivity with 4g supplementation, two
participants demonstrated essential no, and two had a
decrease in insulin sensitivity. In that study, among six
patients, insulin sensitivity found to increase and there-
fore caused to increase in the average insulin sensitivity
in the intervention group [23]. Elusive changes in blood








Weight (Kg) 77.2 ± 13.1 77.6 ± 10.9 73.1 ± 9.4
BMI (Kg/m2) 28.1 ± 2.4 27.4 ± 0.5 27.1 ± 1.8
WC (cm)
Female 86.3 9.2 88.8 ± 7.7 89.0 ± 5.8
Male 96.4 ± 9.8 93.0 ± 7.2 91.1 ± 5.7
WHR
Female 0.84 ± 0.08 0.83 ± 0.04 0.90 ± 0.05
Male 0.95 ± 0.04 0.91 ± 0.03 0.95 ± 0.06
Fat%
Female 41.5 ± 6.0 40.5 ± 7.8 34.1 ± 8.0
Male 28.1 ± 3.8 22.2 ± 7.8 26.1 ± 7.2
Lean%
Female 58.8 ± 5.7 59.5 ± 7.8 65.8 ± 8.0
Male 71.8 ± 3.8 77.7 ± 7.8 73.8 ± 7.2
BMI Body Mass Index, WC Waist circumference, WHR Waist to Hip Ratio, Fat% Perce
α: P values are related to the comparison of variables change differences at the begdifferences in the patients’ responsiveness. This could be
caused by differences in duration of diabetes, patients
‘weight, the severity of insulin resistance and other pa-
rameters measured at baseline and different amounts of
CLA intake from the usual diet. But what is clear, in pa-
tients with normal BMI or overweight, CLA has no or a
little effect on improvement of blood glucose, insulin
and insulin sensitivity [10,33]. So, it is likely that in
obese individuals, CLA causes a small increase in in-
sulin resistance [9,34]. However in our study, CLA
supplementation did not change weight and glycemic
indicators.
In most studies, serum glucose, insulin, and some-
times, fasting pro insulin and C-peptide have been mea-
sured and only indicators of insulin resistance and
insulin sensitivity has been reported. While, several stu-
dies have shown that serum pro insulin, pro insulin/
insulin are better predictors of the risk of heart disease
compared to insulin concentration [35]. In T2D pro in-
sulin, insulin ratio increases, that can be the result of in-
sulin resistance or impaired conversion of pro insulin to
insulin [36]. In the present study, serum concentrations
of C peptide and pro insulin were also measured at the
beginning and end of the study and no changes were
detected.
Recently, using pure isomers of CLA has shown that
the effects of CLA on body composition that is related
to trans-10, cis-12 isomer [6,37]. This fatty acid de-
creases appetite and energy intake in laboratory animals,
increases energy expenditure in the body by increa-
sing expression of Mitochondrial uncoupling proteinmeasurements and body composition in 3 groups








76.9 ± 12.8 77.0 ± 11.1 72.7 ± 9.5 0.86
28.0 ± 2.7 27.2 ± 2.7 26.9 ± 1.8 0.91
84.0 ± 8.3 85.5 ± 10.2 88.0 ± 5.8 0.41
96.2 ± 8.1 91.1 ± 5.7 92.0 ± 5.7 0.51
0.83 ± 0.07 0.82 ± 0.05 0.89 ± 0.06 0.84
0.96 ± 0.05 0.91 ± 0.03 0.94 ± 0.05 0.28
39.3 ± 6.2 38.2 ± 6.3 38.7 ± 7.6 0.24
26.7 ± 7.0 26.8 ± 10.8 27.1 ± 6.4 0.12
60.6 ± 6.2 61.6 ± 6.3 61.0 ± 7.6 0.25
73.2 ± 7.0 73.1 ± 10.8 72.8 ± 6.4 0.12
nt of Body Fat Mass, Lean% Percent of Lean Body Mass.
inning and end of the study between three groups.
Table 4 Mean and standard deviation of fasting and postprandial glycemic indicators, lipid profile, apo B100, MDA and
blood pressure at the beginning and end of study














FBG (mg/dl) 155.5 ± 15.4 154.1 ± 14.1 155.5 ± 20.2 151.3 ± 17.9 156.8 ± 20.6 153.3 ± 19.1 0.52
Fasting insulin (mIU/L) 8.7 ± 6.8 5.1 ± 3.2 10.1 ± 9.6 8.4 ± 6.2 5.6 ± 3.4 10.9 ± 10.2 0.83
Fasting proinsulin
(pmol/L)
19.7 ± 15.0 13.1 ± 9.1 19.7 ± 18.2 18.7 ± 18.1 10.9 ± 7.3 17.1 ± 14.1 0.36
Fasting C peptide
(pmol/L)
701.9 ± 272.0 690.3 ± 356.1 604.4 ± 235.3 672.7 ± 319.1 570.7 ± 259.4 582.6 ± 300.3 0.66
QUICKI 0.328 ± 0.023 0.343 ± 0.040 0.320 ± 0.052 0.334 ± 0.028 0.353 ± 0.040 0.338 ± 0.052 0.81
HOMA-IR 3.34 ± 2.76 2.84 ± 2.50 8.88 ± 19.13 3.07 ± 1.18 2.14 ± 1.18 4.12 ± 4.02 0.54
Fasting proinsulin/insulin 2.73 ± 2.33 2.79 ± 2.54 3.01 ± 2.82 3.32 ± 3.57 2.51 ± 2.25 3.24 ± 3.29 0.53
β cell responsiveness 1.29 ± 0.45 1.37 ± 0.72 1.20 ± 0.54 1.31 ± 0.68 1.16 ± 0.68 1.00 ± 0.65 0.54
HOMA B% 34.56 ± 25.26 30.81 ± 25.19 52.83 ± 76.04 36.36 ± 27.36 24.81 ± 17.81 46.74 ± 46.18 0.44
2h-BS(mg/dl) 191.0 ± 18.6 177.1 ± 21.4 187.4 ± 20.1 174.3 ± 24.8 184.2 ± 28.5 191.2 ± 29.3 0.18
2h- insulin(mIU/L) 20.6 ± 12.3 21.1 ± 12.1 26.3 ± 21.1 14.7 ± 5.7 22.1 ± 12.3 20.1 ± 17.4 0.49
2h-proinsulin(pmol/L) 36.4 ± 22.1 25.3 ± 11.2 38.1 ± 28.2 31.8 ± 28.3 26.5 ± 15.3 36.3 ± 19.6 0.77
2h-C peptide(pmol/L) 1490.4 ± 579.6 1466.1 ± 600.9 1432.4 ± 613.1 1316.1 ± 379.7 1457.1 ± 705.7 1324.1 ± 363.2 0.29
2h- proinsulin/insulin 1.94 ± 1.18 1.58 ± 1.31 2.28 ± 1.77 2.40 ± 2.00 1.49 ± 1.11 2.30 ± 1.18 0.3
HbA1c% 9.43 ± 1.64 10.47 ± 1.59 10.40 ± 1.78 8.93 ± 1.12 9.46 ± 1.70 9.33 ± 1.54 0.68
TG (mg/dl) 185.9 ± 58.9 193.1 ± 78.7 227.2 ± 81.1 172.2 ± 58.8 165.2 ± 58.5 182.8 ± 58.9 0.19
TC (mg/dl) 198.8 ± 27.3 223.5 ± 43.1 234.1 ± 44.3 194.8 ± 37.6 223.2 ± 55.8 227.2 ± 37.2 0.81
LDL-C (mg/dl) 112.9 ± 25.5 132.2 ± 28.5 135.2 ± 40.5 118.8 ± 24.5 144.2 ± 45.9 142.4 ± 33.1 0.97
HDL-C (mg/dl)
Female 47.6 ± 6.1 46.1 ± 5.1 50.6 ± 9.2 40.4 ± 6.2 40.3 ± 8.3 51.3 ± 6.6 0.97
Male 48.1 ± 4.7 56.1 ± 10.1 51.4 ± 12.2 42.8 ± 5.7 48.9 ± 9.1 43.8 ± 4.1 0.6
LDL/HDL
Female 2.5 ± 0.5 2.7 ± 0.5 3.1 ± 1.2 2.9 ± 0.2 3.8 ± 1.6 2.9 ± 0.6 0.22
Male 2.2 ± 0.4 2.4 ± 0.4 2.4 ± 0.8 2.7 ± 0.4 2.9 ± 0.5 3.0 ± 0.6 0.97
Apo B100 (mcg/dl) 61.8 ± 12.4 68.0 ± 13.1 62.6 ± 11.9 53.6 ± 13.0 58.8 ± 14.8 62.7 ± 14.2 0.84
MDA (mcmol/L) 14.2 ± 6.0 12.1 ± 5.1 11.6 ± 6.7 16.1 ± 8.1 16.5 ± 8.0 11.2 ± 6.7 0.62
Systolic blood pressure
(mmHg)
126.5± 12.8 115.4±10.1 130.1± 23.1 125± 13.5 115.2± 9.3 128.3± 19.1 0.81
Diastolic blood pressure
(mmHg)
87.6± 8.3 78.1± 7.3 84.4± 11.1 83.4± 12.4 79.1± 7.2 84.3± 9.2 0.21
FBG Fasting Blood Glucose , QUICKI Insulin sensitivity Index, HOMA-IR Homeostasis Model of Assessment Insulin Resistance, HOMA B% Beta cell function index,
HbA1c% percent of glycosilated hemoglobin, 2h-BS 2 Hour postprandial Blood Glucose, TG Triglyceride, TC Total Cholesterol, LDL-C low Density Lipoprotein
Cholesterol, HDL-C High Density Lipoprotein Cholesterol, Apo B100 Apoprotein B100, MDA Malondialdehyde.
Group A- receiving 3.0 g CLA/d (3×1 g capsules; a 50:50 isomer blend of c-9, t-11 and t-10, c-12 CLA) with 100 IU/d vitamin E, Group B- receiving 3.0 g CLA/d with
vitamin E placebo, Group C- receiving CLA placebo and vitamin E placebo.
α: P values are related to the comparison of variables change differences at the beginning and end of the study between three groups by ANCOVA test.
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http://www.jdmdonline.com/content/12/1/422 (UCP2). CLA decreases lypogenesis through inhibi-
tion of lipoprotein lipase (LPL2), fatty acid synthase,
acylcoenzyme A carboxylase and PPAR-γ. Also, CLA in-
creases fat oxidation. Thus, CLA reduces fatty cell size
with no effect on cell numbers [5]. Changes in weight and
body composition observed in human studies are not as
changes observed in experimental animals. In some hu-
man studies, CLA supplementation was associated todecrease in body weight and fat mass [21,38], but in others
there was not any changes in body composition [39,40]. It
seems that factors such as current state of health, degree
of obesity, and activity levels might influence the impact
that CLA supplementation has on altering body compos-
ition. Also, given the fact that the molecular mechanism
of CLA is through changing gene expression [12,39], the
differences in gene expression in several species can cause
Table 5 Mean and standard deviation of inflammatory indicators, leptin, adiponectin, Fibrinogen and PAI-1 at the
beginning and end of study














IL-1β (pg/ml) 17.6 ± 10.9 20.2 ± 15.1 14.3 ± 7.2 13.5 ± 7.2 13.5 ± 7.4 10.7 ± 2.8 0.17
IL-6 (pg/ml) 4.1 ± 2.8 4.1 ± 1.4 4.4 ± 2.1 3.5 ± 1.5 3.2 ± 0.6 4.3 ± 3.2 0.14
CRP (ng/ml) 2138.2 ± 3469.2 2083.0 ± 2362.5 1922.9 ± 2482.5 1159.8 ± 1022.7 1533.8 ± 1189.8 1564.0 ± 1943.3 0.38
TNF-α (pg/ml) 15.1 ± 2.9 14.9 ± 2.5 14.4 ± 3.5 12.3 ± 2.9 11.9 ± 2.0 11.9 ± 1.9 0.74
Leptin (ng/ml)
Female 23.40 ± 12.42 23.44 ± 11.57 10.74 ± 4.79 20.13 ± 14.91 14.55 ± 6.10 6.61 ± 0.98 0.54
Male 6.47 ± 5.66 9.32 ± 7.66 4.90 ± 2.60 6.92 ± 6.48 5.86 ± 5.47 2.98 ± 1.57 0.11
Adiponectin (ng/ml) 61.43 ± 19.96 76.0 ± 26.82 62.38 ± 26.74 62.06 ± 21.24 71.89 ± 29.10 61.90 ± 19.96 0.55
Fibrinogen (mg/dl) 67.0 ± 6.4 69.8 ± 7.1 68.9 ± 7.1 63.1 ± 8.7 64.4 ± 7.8 61.3 ± 9.3 0.56
PAI-1 (ng/ml) 18.5 ± 16.2 17.3 ± 11.2 14.8 ± 6.0 18.0 ± 16.6 20.7 ± 18.1 15.0 ± 11.6 0.73
IL-1β interleukin 1 beta, IL-6 interleukin 6, CRP C Reactive Protein, TNF-α Tumor Necrosis Factor, PAI-1 Plasminogen activator inhibitor-1.
Group A- receiving 3.0 g CLA/d (3×1 g capsules; a 50:50 isomer blend of c-9, t-11 and t-10, c-12 CLA) with 100 IU/d vitamin E, Group B- receiving 3.0 g CLA/d with
vitamin E placebo, Group C- receiving CLA placebo and vitamin E placebo.
α: P values are related to the comparison of variables change differences at the beginning and end of the study between three groups by ANCOVA test.
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http://www.jdmdonline.com/content/12/1/42contradictory results. Regarding human studies, Belury
and colleagues showed that plasma levels of CLA has been
inversely associated with body weight and the trans-10,
cis-12 isomer is responsible for this negative correlation
and biological active responsible for weight change in
people with type2 diabetes. Short duration of intervention
in these studies may be one reason of elusive changes in
anthropometric measurements, body fat and lean body
mass. In the present study the daily intake of 3g of CLA
capsules for eight weeks, did not occur significant changes
in weight, BMI, waist circumference and body fat mass
percentage. However, the results of this study is not com-
parable to the results of separated isomers, because the
commercial CLA supplements contain the two active iso-
mer in equal ratio, so each isomers differentially act on ex-
pression of related enzymes [12]. In long-term studies of 6
and 12 months using supplemental CLA isomers in equal
ratio, weight loss and a reduction in body fat mass have
been reported [41,42]. It seems that appearing of CLA ef-
fects on weight and body composition, more time is
needed. As in our study which lasted eight weeks, no
changes in physical parameters were seen. However, in
some three months and even six-week studies changes in
body weight and fat mass have been seen [42,43]. The dif-
ferences in individuals’ response in expression of enzymes
associated with energy expenditure and body composition,
type of drugs and CLA dietary intake can justify the in-
consistency in the results of studies. As this study was on
glucose-lowering drug consumers that may interfere with
the mechanisms of CLA in some metabolic pathways.
Also, calculation of dietary CLA intake was not possible.
In this study, daily supplementation with 3 g of CLA
capsules alone and combined with 100 IU of VitE foreight weeks compared to placebo, did not result in sig-
nificant changes in serum triglycerides, total cholesterol,
LDL, HDL cholesterol and apoB100. Some animal stud-
ies using pure CLA isomers have shown that cis-9,
trans-11 isomer lead to lowering triglyceride levels and
plasma free fatty acids and trans-10, cis-12 isomer lead
to increasing plasma free fatty acids and LDL cholesterol
[2] that is confirmed by human studies [21]. However,
the results of equal ratio of isomers are contradictory. In
a study on patients with type2 diabetes, taking 3g of
CLA supplementation for 8 weeks, resulting in increased
HDL2 cholesterol and decreased LDL to HDL choles-
terol ratio [7], although in another study, reduced serum
HDL cholesterol following 12 weeks of supplementation
has been reported [44]. In other studies with 6 weeks
and 6 months duration, no significant changes were
shown in serum lipids and Apo proteins [33,43]. Overall,
the effects of commercial CLA capsules on lipids profiles
are unknown. Further studies should be done in this re-
gard to identify the mechanisms of CLA in regulating
gene expression involved in lipid metabolism.
In our study, it was not shown any change in systolic
and diastolic blood pressure. In two animal studies, CLA
has reduced blood pressure [45,46]. In another study,
trans-10, cis-12 isomer lowered blood pressure and cis-9,
trans-11 did not affect [47]. CLA effects on blood pressure
could be related to the pathway of eicosanoids production.
Inhibition of Arashidonic acid released from cell mem-
branes and cyclooxygenase by CLA has been reported
[11].
In our study, 3 g daily CLA capsules alone and com-
bined with 100 IU of VitE for eight weeks did not affect
any inflammatory parameters IL-1 beta, interleukin-6,
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http://www.jdmdonline.com/content/12/1/42TNF-α, CRP, Serum leptin and adiponectin. Animal stu-
dies show that trans-10, cis-12 isomer increases indicators
of inflammation and cis-9; trans-11 is associated with re-
duction of inflammatory indicators [12]. In this way the
CLA supplementation in rats leads to decreased TNF-α
and in mice increased it [19]. In some human studies,
CLA did not affect serum inflammatory parameters [7],
but in the some others led to increase in these me-
diators [45], in the present study also no significant
changes developed.
In one study, CLA supplementation reduced leptin
and adiponectin [8] and in two other studies any chan-
ges are not mentioned [9,28]. In the present study changes
in serum leptin and adiponectin showed no statistically
differences among the three groups.
In our study there was not seen any significant diffe-
rences in serum fibrinogen and PAI-1 changes among
three groups. Also, no information is regarding the ef-
fects of CLA supplementation on these variables.
In the present study 3 g of CLA capsules alone and
combined with 100IU VitE did not make a difference in
the oxidative stress index, MDA compared with placebo.
In some studies, taking an active CLA isomer has in-
creased lipid peroxidation indexes, including urinary ex-
cretion of isoprostaglandins [9,21].
One limitation of this study is that estimation of die-
tary and serum CLA was not possible. Differences in
dietary intake and thus serum CLA levels can affect pa-
tients’ responsiveness to supplementation. Also, the use
of 2-d diet records may not accurately reflect changes in
calories during intervention. Duration of this study was
8 weeks. It may be required longer time to appearance
CLA effects.
Because of insufficient information regarding the mo-
lecular mechanisms of CLA in humans, human cell cul-
ture studies are suggested.
Conclusion
Overall, our results show that commercial CLA supple-
mentation alone or combined with VitE for 8weeks, does
not significantly affect glycemic indicators, body compo-
sition, lipid concentrations, indicators of inflammation,
coagulation, leptin, adiponectin, MDA and blood pressure
in type2 diabetes, but there was a significant trend to in-
crease in MDA and decrease in apoB100 among CLA
consumers.
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